Buprenorphine tapering schedule and illicit opioid use

Opioid abstinence reinforcement delays heroin lapse during buprenorphine dose tapering.

A positive reinforcement contingency increased opioid abstinence during outpatient dose tapering (4, 2, then 0 mg/day during Weeks 1 through 3) in non-treatment-seeking heroin-dependent volunteers who had been maintained on buprenorphine (8 mg/day) during an inpatient research protocol. The control group (n=12) received $4.00 for completing assessments at each thrice-weekly visit during dose ta...

Utilizing buprenorphine–naloxone to treat illicit and prescription-opioid dependence

OBJECTIVES To review current evidence on buprenorphine-naloxone (bup/nx) for the treatment of opioid-use disorders, with a focus on strategies for clinical management and office-based patient care. QUALITY OF EVIDENCE Medline and the Cochrane Database of Systematic Reviews were searched. Consensus reports, guidelines published, and other authoritative sources were also included in this review...

Illicit use of buprenorphine/naloxone among injecting and noninjecting opioid users.

OBJECTIVES We examined the use, procurement, and motivations for the use of diverted buprenorphine/naloxone among injecting and noninjecting opioid users in an urban area. METHODS A survey was self-administered among 51 injecting opioid users and 49 noninjecting opioid users in Providence, RI. Participants were recruited from a fixed-site syringe exchange program and a community outreach site...

Changes in illicit opioid use across Canada.

Comparison of Buprenorphine and Buprenorphine/naloxone in Detoxification of Opioid-dependent Men

Background: Buprenorphine sublingual tablets are now available in Iran for opioid detoxification in clinics. Aim of the present study was to compare the efficiency of buprenorphine with buprenorphine/naloxone in short-term detoxification in a group of Iranian male opioid-dependent patients. Methods:A double-blind trial was carried out on a gro...